Pfizer to buy back plant and then sell or shutter; Cold chain breaks are culprit in child vax deaths;

> Pfizer will buy back a manufacturing facility in Rouses Point, NY, from current owner Akrimax Pharmaceuticals and will either sell or shutter it by 2013. News

> Cold chain breakdowns between production to the last mile are the leading culprit in the increased death rate of Indian children after immunization. Story

> The FDA has reportedly inspected the manufacturing plants of at least six Indian drugmakers, raising their hopes of exporting medicines to the U.S. Article

> Despite calling them "serious offenses," a judge has sentenced Graham Dawson to two years of community service and 100 hours of unpaid work for supplying fake Viagra from China to customers in the U.K. News

> Following the lead of governments and regulators around the world, India has pushed back the deadline for a track and trace initiative, this one based on barcode technology for export consignments of drugs. Story

> Bausch & Lomb will launch a pharmaceutical business in India through a strategic collaboration with Micro Labs, a Indian drug manufacturing organization. Report

> Mumbai-based hard capsule manufacturer ACG Worldwide plans to invest $135 million over three years to expand manufacturing capacity. Item

> OctoPlus says it has signed a process development and manufacturing contract a pharmaceutical company headquartered in Denmark. Item

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)